The Benefits Of Drug Repositioning By Dr Aris Persidis Drugs in development, on the market, or those that are shelved because of lack of efficacy, are excellent starting points for further development. Finding new indications for such drugs will benefit patients who will see a potential new therapy sooner, will… Read More
Protein Biomarker Immunoassays: Opportunities and Challenges By Dr M. Walid Qoronfleh and Dr Klaus Lindpaintner With the biopharma industry under heavy pressure, transforming the scientific interchange between the laboratory and the clinic is exceedingly critical. Realising the costly toll of drug attrition in late-stage development, many companies are turning to… Read More
Current Trends in Label-Free Drug Discovery Technologies By Philip Rawlins Drug Discovery Label-free technologies have been used throughout drug discovery for the detection and characterisation of molecular interactions. The implementation of automated systems, increased sensitivity and the development of new technologies have recently broadened the use of label-free methods from… Read More
Mass Spectrometry is a mature technology predicated on a premise demonstrated almost a century ago. It is widely used in most scientific disciplines involving basic research or industrial endeavours, that require accurate and precise measurement of elemental and molecular components. More recently it has become one of the foundation technologies… Read More
Biomarkers Make Their Mark on Current Research and Drug Development Trends By Stephane Parent and Dr Gregory Cosentino Biomarkers continue to become increasingly relevant in research and healthcare applications, as evidenced by the global market for products involved in their identification, validation, and use estimated at $8.3 billion in 2007… Read More
Enterprise ELNs as a Foundation for Preclinical Drug Development By Simon Beaulah, Dr Paul Denny- Gouldson and Dr Scott Weiss To have real business impact within preclinical drug development, Enterprise ELNs (Electronic Laboratory Notebooks) must provide a secure, scalable and searchable data management backbone across all disciplines focused on development… Read More
Tracking HTS Assay Development Time: Opportunity for improving drug discovery By Dr Jennifer Hartigan, Cindy Liu and William Downey High throughput screening (HTS) assays are developed more quickly now due to advances in technology, improved liquid handling and sensitive detection, as well as increased communication between scientists in high throughput… Read More
Towards Unbiased Biomarker Discovery Dr Jens Hoefkens High-throughput molecular profiling technologies are routinely applied for biomarker discovery to make the drug discovery process more efficient and enable personalised medicine. The ability to find novel biomarkers rests on large-scale data generation and unbiased data analysis. Over the past decade, biomarker discovery… Read More
By Dr Stephen Naylor and Toby Cole In this article we describe the current state of Companion Diagnostics and its impact on the pharmaceutical sector, and the need for Companion Diagnostics in the drug discovery and development process. This perspective is augmented by a consideration of the development of Companion… Read More
Custom Carbon-14 Radiolabelling: Investing to meet new challenges By Dave Roberts One consequence of an increasing demand from regulators for robust quantitative data on the behaviour of new drugs in man and for information on the fate of pharmaceuticals in the environment, has been an increase in demand for carbon-14… Read More
Recent Technology Advances Transforming Pharmaceutical Drug Discovery and Development By Dr Coiln Brenan, and Dr Bill LaMarr The last decade has seen rapid technological progress but with increasing demands for safe and efficacious drugs, technological solutions that reduce the barriers to clinical success will be of more interest than those… Read More
Restructuring Proteomics to Enable Personalised Cancer Care By Dr Henry Rodriguez The genomics community has made great strides in our understanding of the molecular basis of cancer and these advances are slowly beginning to change the way we diagnose and treat patients. But genomic studies alone cannot capture the complete… Read More
The Microplate Market Past, Present and Future By Dr Peter Banks Microplates and the peripheral markets of liquid handling and detection technologies exist within almost all laboratories performing assays. This article discusses what, if any, are their growth expectations and whether there are new technologies on the horizon that could… Read More
By Dr Anil Vasudevan Since the original publications on the benefits of conducting organic reactions in a microwave by Gedye (1) and Majetich (2) in the mid-80s, the uptake of this technique was sluggish at best for the next 12-14 years. However, the past few years have witnessed an explosion… Read More
Lean Six Sigma - Its application to drug discovery By Clare Hammond and Charles J O'Donnell In an increasingly competitive world, the race between pharmas to get high quality candidate drugs to market is on. Contributing to this success is the discovery phase of lead optimisation. The application of Lean… Read More
Progress in Systems-Based Analysis of Cellular Signalling By Dr Jeffrey A. Radding Drug discovery currently focuses on targeted approaches, relying on validation of the target as a disease driver. However, the underlying biological complexity of disease often frustrates these attempts at therapeutic intervention, resulting in high failure rates due to… Read More